Journal of Neurogastroenterology and Motility : eISSN 2093-0887 / pISSN 2093-0879

Table. 3.

Changes in Gastrointestinal Symptom Scores From Baseline at Week 4

GIS Mosapride citrate SR group Mosapride citrate CR group Difference [95% CI]a P-value
PPS n = 51 n = 49
Baseline 13.55 ± 5.21 13.84 ± 5.32 0.721c
Week 4 3.51 ± 3.85 2.98 ± 3.11
Changeb –10.04 ± 4.45 –10.86 ± 5.53 0.82 [–1.17, 2.81] 0.643c
In group P-value < 0.001d < 0.001d
FAS n = 57 n = 57
Baseline 13.55 ± 5.00 14.07 ± 5.58 0.541c
Week 4 3.49 ± 3.82 3.70 ± 5.22
Change –9.86 ± 4.48 –10.37 ± 6.23 0.51 [–1.51, 2.52] 0.820c
In group P-value < 0.001d < 0.001d

GIS, gastrointestinal symptom scores; PPS, per-protocol set; FAS, full analysis set.

aInter-group Difference [95% CI] = mosapride citrate SR-mosapride citrate CR 95% CI based on t test.

bChanges in score related to symptoms (week 4-baseline).

cWilcoxon rank sum test.

dWilcoxon signed rank test.

J Neurogastroenterol Motil 2021;27:87~96 https://doi.org/10.5056/jnm20061
© J Neurogastroenterol Motil